Study title: Phase III trial on the persistence of antibodies 5 years after a primo-vaccination and 4 years after a first booster with PENTAVAC® vaccine and the immunogenicity and safety of a second booster with TETRAVAC-ACELLULAIRE® vaccine at the age of 5-6 years.
Type of medicine: Non-centrally authorised vaccines | |||||
Therapeutic area: Bacterial Infections and Mycoses | |||||
Brands: Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine | |||||
ATC code: J07CA02 | |||||
Document link: | |||||
Document date: 2011-09-15 | |||||
Study number: F992I015 | |||||
EudraCT number: | |||||
Scope of study: | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |